Leuprorelin Sandoz (Leuprorelin)

• Leuprorelin acts on the GnRH pathway to suppress sex‑hormone production in several hormone‑sensitive diseases.
• Prostate cancer: reduces testosterone levels to slow tumor growth.
• Endometriosis: lowers estrogen to alleviate pelvic pain and lesion progression.
• Uterine fibroids: diminishes estrogen-driven fibroid growth.
• Precocious puberty: delays early sexual development by suppressing gonadotropins.
• Premenopausal breast cancer: lowers estrogen to inhibit tumor proliferation.

• Leuprorelin is a synthetic GnRH analog that initially stimulates pituitary GnRH receptors, causing a transient surge in LH and FSH, followed by receptor down‑regulation. This sustained down‑regulation suppresses LH and FSH secretion, leading to markedly reduced ovarian or testicular sex‑hormone production, thereby controlling hormone‑dependent disease processes.

Leuprorelin may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects

• Hot flashes and sweating.
• Injection site pain or erythema.
• Decreased libido or sexual dysfunction.
• Mood changes, including depression.
• Headache or fatigue.
• Transient increase in hormone levels (flare effect).

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty.
• Bone density loss leading to osteoporosis.
• Cardiovascular events such as myocardial infarction or stroke.
• Liver function abnormalities.
• Persistent hypo‑gonadism requiring hormone replacement.

• Before initiating therapy, clinicians should consider several safety measures.
• Baseline assessment: obtain hormone levels and imaging to confirm indication.
• Cardiovascular risk: evaluate history of heart disease before long‑term use.
• Bone health: monitor bone mineral density, especially in prolonged therapy.
• Psychiatric status: watch for depression or mood disorders during treatment.
• Drug interactions: review concomitant medications that may affect hormone pathways.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other agents that influence hormonal or metabolic pathways.

Major Interactions (Avoid)

• Combined use with estrogen‑containing therapies, which may counteract the drug’s suppressive effect.
• Concurrent strong CYP3A4 inducers that could alter hormone metabolism.

Moderate Interactions (Monitor Closely)

• Anticoagulants, as hormonal changes may affect coagulation parameters.
• Steroids or glucocorticoids, which can modify endocrine responses.
• Medications affecting bone turnover, requiring closer monitoring of bone health.